G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes
Authors:
- 15 November 2013
- journal article
- research article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 37 (4) , 435-439
Abstract
With growing needs for new antidiabetic drugs which are safe and effective alone or in combination with existing drugs, G-protein coupled receptor 40 (GPR40) has drawn a considerable attention as a potential therapeutic target for type 2 diabetes. As GPR40 agonist may offer advantages to commonly used agents, by acting ambient glucose dependent manner which mechanistically leads to reduced risk of developing hypoglycemia. Since deorphanization in 2003, development of small molecule GPR40 agonists has been spurred by several research groups. There are a number of lead molecules targeting GPR40, and among these molecules TAK-875 (full agonist) and AMG 837 (partial agonist) advanced into clinical stage.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in RodentsPLOS ONE, 2012
- Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetesCore Evidence, 2012
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet, 2012
- TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic RatsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Review: Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesisTherapeutic Advances in Endocrinology and Metabolism, 2010
- Overexpression of GPR40 in Pancreatic β-Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic MiceDiabetes, 2009
- Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in MiceDiabetes, 2008
- Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small moleculesBritish Journal of Pharmacology, 2006